Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1David A. Barbie, William C. Hahn, Pablo Tamayo et al.|Nature|2009Cited by 4.2k
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosisRoss L. Levine, D. Gary Gilliland, Martha Wadleigh et al.|Cancer Cell|2005Cited by 3k
Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignanciesOmar Abdel‐Wahab, Ross L. Levine, Igor Dolgalev et al.|Blood|2009Cited by 718
Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412Joseph D. Growney, D. Gary Gilliland|Blood|2005Cited by 250
Transformation of hematopoietic cell lines to growth-factor independence and induction of a fatal myelo- and lymphoproliferative disease in mice by retrovirally transduced TEL/JAK2 fusion genesJuerg Schwaller, D. Gary Gilliland|The EMBO Journal|1998Cited by 250